secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2022-06-23T23:59:59+00:00
Accession:  0000950170-22-012039
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical shareholders approve doubling authorized common stock to 200M shares
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized common shares from 100M to 200M (32.6M for, 4.4M against, 6.0M abstain).
- Directors George Lasezkay and Christy Shaffer elected with 25.9M and 24.8M votes for, respectively.
- Advisory vote on executive compensation passed with 27.6M for, 3.0M against; annual frequency chosen.
- Ratification of Ernst & Young as auditor for FY2022 received 42.9M votes for, 88.8K against.
- Annual meeting turnout: 43.0M of 60.2M shares represented (71.55% quorum).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022012039/0000950170-22-012039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022012039/clsd-20220622.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer